BOTHELL, Washington, U.S.A., and SEONGNAM, Republic of Korea, February 21, 2017 - CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Genexine, Inc. (KOSDAQ: 095700), an innovative biotechnology company focused on immuno-oncology, metabolic and orphan diseases, today announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of Genexine’s GX-H9.
Agreement covers process development and manufacture of CytoDyn’s PRO 140
Bothell, WA, Copenhagen, Denmark, Berkeley, CA, and Tokyo, Japan– February 15, 2017 –CMC Biologics, a
global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and CytoDyn Inc., a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection, announced today they have entered into an agreement for the process development and commercial manufacture of CytoDyn’s PRO 140.
CMC Biologics to continue to provide CDMO services to the biopharma marketplace
Bothell, WA, Copenhagen, Denmark, Berkeley, CA, and Tokyo, Japan– December 19, 2016 – CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins and AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announced today that they have entered into a definitive agreement with CMC Biologics’ shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100% of CMC Biologics’ shares. This acquisition is expected to close in January 2017.
CMC Biologics Copenhagen Facility site head Patricio Massera, was honored to participate in the recent Danish State Visit to Korea
CMC Biologics was chosen for inclusion in the state visit, along with representatives from other select Danish companies in the Health Industry, for participation in a Denmark- Korea Roundtable Meeting on Health.
Cerbios-Pharma will Provide Highly Cytotoxic Drug Payloads and Conjugation Services for Manufacture of ADC Drug Substance
Oncotec Pharma will Provide Sterile Filling and Lyophilization of Cytotoxic Active Ingredients for ADCs
Bulk Drug Intermediate Produced in CMC Biologics’ Copenhagen, Denmark Facility
COPENHAGEN, Denmark and BOTHELL, Wash. – June 16, 2016 – CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, today announced that it will supply bulk drug intermediate for CSL Behring’s recently FDA-approved product, AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A, to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and the perioperative management of bleeding.
Addition of a Bioreactor 3PACK™ Production Facility to its Copenhagen Facility Provides Additional Flexible Soultions for Clients
BOTHELL, Wash., Berkeley, Calif., USA, and COPENHAGEN, Denmark – June 2, 2016 (GLOBE NEWSWIRE) – CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, announced today that, as part of its ongoing global manufacturing capacity expansion, it has completed the first stage of the expansion for its manufacturing facility in Copenhagen, Denmark with the addition of a single-use Bioreactor 3PACK™ facility. The Bioreactor 3PACK™ configuration consists of three 2,000L single-use production bioreactors and associated seed train for scale up, allowing for flexible production with scales from 2,000L to 6,000L in a single production suite. The bioreactors can be run singly, simultaneously, sequentially or in staggered fashion to achieve desired production needs. The 3PACK™ line is ready for production runs in June 2016.
Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Factor Vlla CB 813d
Catalyst Plans to Initiate Clinical Pivotal Trial in Hemophilia A and B "Inhibitor" Patients in 2017
SOUTH SAN FRANCISCO, Calif. and BOTHELL, Wash. and COPENHAGEN, Denmark – May 24, 2016 (GLOBE NEWSWIRE) – Catalyst Biosciences, Inc. (NASDAQ:CBIO), a leading biotechnology company focused on discovering and developing novel protease therapeutics for treatments of serious medical conditions in the fields of hemostasis and anti-complement, and CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, today announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of CB 813d, Catalyst’s next-generation long-acting Factor VIIa product. Catalyst is developing CB 813d for the treatment of hemophilia A and B inhibitor patients.
Life Science Leader Awards CMC Biologics for it Quality, Reliability, Capabilities, Expertise, Compatibility, State-of-the-Art and Innovation
SEATTLE, WA, BERKELEY, CA, and COPHENHAGEN, DENMARK – March 29, 2016 – CMC Biologics, Inc., a world leader in contract development and manufacturing of therapeutic proteins, today announced its recognition by Life Science Leader in their CMO Leadership Award Ceremony. The ceremony, which took place in New York on March 16, 2016, recognized CMC Biologics as the leader in all five categories—Quality, Reliability, Capabilities, Expertise and Compatibility.
Will Provide an Efficient End-to-End Solution for Development and Manufacture of ADCs
COPENHAGEN, Denmark and DESSAU, Germany, February 17, 2016. CMC Biologics A/S, a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, and IDT Biologika GmbH, a privately-held life-science company with a 95 year history of expertise in research, development and manufacture of biologics for human and animal health, announced the formation of a strategic collaboration to provide a complete and efficient solution for the manufacture of antibody drug conjugates (ADCs).